News & Updates

A substudy of the VANISH2 trial has found catheter ablation to be superior to sotalol in reducing ventricular tachycardia (VT) and VT-related events in sotalol-eligible patients. In those with more severe heart disease or VT storm, ablation demonstrates similar efficacy to amiodarone.

The use of glucagon-like peptide-1 receptor agonists (GLP1-RAs) better protects against major adverse cardiovascular events (MACE) as compared with dipeptidyl peptidase-4 inhibitors (DPP-4is) in patients across the spectrum of kidney disease, as shown in a retrospective study.

In adults with cardiovascular‐kidney‐metabolic (CKM) syndrome, higher intake of omega‐3 polyunsaturated fatty acids (n‐3 PUFAs) has been associated with less severe CKM stage and lower mortality in new research.

The use of GLP-1 receptor agonists (RAs) is associated with improved testosterone levels and semen quality in men with metabolic issues, while maintaining gonadotropin function, reports a study.

Treatment with budesonide once daily effectively maintains endoscopic and histologic remission in most patients with eosinophilic esophagitis (EoE), which is similar to reported outcomes with twice daily dosing, according to a study.

In the treatment of patients with moderately severe chronic obstructive pulmonary disease (COPD), the use of bisoprolol has no significant effect on overall cardiorespiratory health, all-cause mortality, or serious cardiorespiratory events when compared with placebo, as shown in a phase III study.

Among adults with obesity, either bariatric surgery or glucagon-like peptide 1 receptor agonists (GLP-1 RAs), such as semaglutide or tirzepatide, led to substantial fat mass (FM) loss and moderate fat-free mass (FFM) loss, according to a recent study. 

In adults with type 2 diabetes (T2D), treatment with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) confers better protection against chronic and acute kidney events compared with a glucagon-like peptide-1 receptor agonist (GLP-1RA), according to a comparative effectiveness study with a target trial emulation design.

Anti-inflammatory treatments appear useful in improving depressive symptoms and anhedonia in patients with depression who exhibit an inflammatory phenotype, results of a systematic review and meta-analysis have shown.